Stockreport

CorMedix: Raised Guidance, NOL Confidence, And Rezzayo Optionality Justify A Hold Rating [Seeking Alpha]

CorMedix Inc.  (CRMD) 
NASDAQ:AMEX Investor Relations: cormedix.com
PDF CRMD raised FY25 guidance, but long-term risks remain due to TDAPA reimbursement changes, pricing pressure, and customer concentration. The Melinta acquisition and Re [Read more]